Market Update: Bristol-Myers Squibb Company (NYSE:BMY) – First Randomized Study Evaluating Opdivo (nivolumab)+Yervoy (ipilimumab) Regimen Demonstrates Superior Efficacy Versus Yervoy Alone in Patients with Previously Untreated Advanced Melanoma

[Business Wire] – Bristol-Myers Squibb Company today announced positive results from a Phase II trial , evaluating the Opdivo +Yervoy regimen versus Yervoy alone in patients with previously untreated advanced melanoma. Read more . . . → Read More: Market Update: Bristol-Myers Squibb Company (NYSE:BMY) – First Randomized Study Evaluating Opdivo (nivolumab)+Yervoy (ipilimumab) Regimen Demonstrates Superior Efficacy Versus Yervoy Alone in Patients with Previously Untreated Advanced Melanoma Similar Articles: Stock Update (NYSE:BMY): Bristol-Myers Squibb Signs Exclusive Agreement with Bavarian Nordic for PROSTVAC®, a Prostate-Specific Antigen-Targeting Cancer Immunotherapy Market Update: Bristol-Myers Squibb Company (NYSE:BMY) – U.S. Food and Drug Administration Accepts Supplemental Biologics License Application for Yervoy® (ipilimumab) as Adjuvant Treatment for Patients with Stage 3 Melanoma Who Are at High Risk of Recurrence Market Update (NYSE:BMY): Study of Next-Generation Investigational HIV-1 Maturation Inhibitor Shows Positive Results in Preventing Viral Replication via Different Mechanism of Action Than Current Therapies